Media stories about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medidata Solutions earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1187472033589 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of research firms have recently weighed in on MDSO. ValuEngine cut Medidata Solutions from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. TheStreet upgraded Medidata Solutions from a “c+” rating to a “b-” rating in a report on Monday, March 12th. BidaskClub upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Royal Bank of Canada set a $82.00 price target on Medidata Solutions and gave the stock a “hold” rating in a report on Thursday, February 8th. Finally, Needham & Company LLC lowered their price target on Medidata Solutions to $75.00 and set a “buy” rating for the company in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $82.07.
Medidata Solutions stock traded down $0.54 on Thursday, reaching $66.53. The company had a trading volume of 136,712 shares, compared to its average volume of 574,382. Medidata Solutions has a 1 year low of $54.91 and a 1 year high of $85.92. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.19. The firm has a market cap of $3,867.93, a price-to-earnings ratio of 75.06, a price-to-earnings-growth ratio of 3.43 and a beta of 1.56.
In other Medidata Solutions news, CEO Tarek Sherif sold 26,836 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $70.25, for a total value of $1,885,229.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $66.30, for a total value of $132,600.00. Following the completion of the sale, the chief financial officer now directly owns 94,744 shares in the company, valued at approximately $6,281,527.20. The disclosure for this sale can be found here. Insiders sold a total of 35,836 shares of company stock worth $2,495,689 in the last ninety days. 5.80% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Medidata Solutions (NASDAQ:MDSO) Getting Somewhat Positive Press Coverage, Report Shows” was published by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/22/medidata-solutions-mdso-earning-somewhat-positive-media-coverage-report-shows/1927593.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.